We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.80 | 1.93% | 201.00 | 199.20 | 203.50 | 202.50 | 194.20 | 199.00 | 240,015 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.31 | 194.61M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/6/2022 11:32 | Having been reading badger60 articles on this forum I thought to myself self I am going to end it now and commit suicide 😭😭 than I read Harry's article's than I think to myself hanging on boy we are on the way up and their is a lot to live for 🤣🤣 Great articles harry as always. | you for me | |
21/6/2022 11:14 | Dominic, I can confirm that there is a note out this morning from a leading investment bank , confirming that the vector in YTB323 is OXB's Lentivector , so this should be important and excellent news for us . As an aside they give an updated price target of £10.60 . Tuco. | tuco 1 | |
21/6/2022 11:07 | I can confirm that they ARE using our lenti. That knowledge now explains why we were agreeing to supply less volume but are free to use elsewhere. The method implies less volume inherently will be needed per patient, but numbers of patients should grow, and therefore royalties should be bigger. | dominiccummings | |
21/6/2022 10:52 | Whist we're all in a more upbeat mood today - share price climbing, lovely weather, summer solstice and first day of the druid shooting season, can I take the opportunity to remind us all of a positive here which may well come under the category of elephant in the room:- We have a long and fruitful relationship with Novartis, being a key / essential supplier to their first in man / first approved CAR-T with our LentiVector which is tied to their licence / approval. Novartis are about to move up a gear with T-Charge in their next generation CAR-T and if anyone remembers the Novartis presentation slide that I linked to in my post 3321 then they say clearly that they are using the same vector as Kymriah (i.e. ours) Look at the last line from the top banner (below) INTRODUCTION • Extended T-cell culture periods in vitro deplete the chimeric antigen receptor (CAR)-T cell final product of naive and stem cell memory T-cell (Tscm) subpopulations that are associated with improved antitumor efficacy1 • YTB323 is an investigational, autologous CD19-directed CAR-T cell therapy – YTB323 expresses the same validated CAR as tisagenlecleucel (Kymriah®), an approved CAR-T cell therapy for pediatric/young adult B-cell acute lymphoblastic leukemia (B-ALL) and relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)2,3 – YTB323 is produced using a simplified and innovative platform called T-Charge™, which reduces the manufacturing process time to <2 days • The new T-Charge™ manufacturing platform was evaluated in a preclinical setting compared to traditional manufacturing (TM) of a CAR-T product using the same lentiviral vector (CTL*019) | harry s truman | |
21/6/2022 08:42 | Things tend to come right as long as the company is fully funded, well managed etc. There is the old adage it’s time in the market not necessarily timing. | chillpill | |
21/6/2022 08:29 | I'm pleased for you with that CP. I realise that there are more investment mantras than can fit into one very big book, but most of them revolve around the idea that if you are patient then a decent stock will come good (eventually). There are some videos which are stuck at a certain point in time now (for obvious reasons) but I always enjoy listening to the YouTube speeches where Peter Lynch is reminiscing on life and his time in charge of Magellan (29% average annual return over a 20+ year period). Quite humorous but a lot of common sense in there. Even with all the information available at a click today, the market still does greed and fear. If you can hold fast during the fear phase then it's usually ok. | harry s truman | |
21/6/2022 07:58 | One of the more bizarre investments I made was in William Hill. I bought it in Jan 2020 as a steady growth stock with yield at 180p. Covid struck. Price fell. Went out of the index. Stock briefly hit 20p and within 4 months it was bid for at 272p. I managed to average down a bit at 40p but was complete madness. Fortunately I made decent money in the end! | chillpill | |
21/6/2022 07:18 | Buying after the forced selling by index funds generally works especially if the fundamentals remain the same. I agree it could bounce to £6 quite quickly. | chillpill | |
20/6/2022 19:43 | Could be a dead cat but i doubt it.Should retest 6 quid at a minimunm | steeplejack | |
20/6/2022 19:09 | Harry I totally arree with almost everything you said.....but I did post a while back before the crash about our over perceived reliance on covid stuff and to focus on ground breaking core science cart t ect I didn't sell as price dropped and are here for long term...never a better time to buy!! | timax333 | |
20/6/2022 17:48 | tim, God bless you for the no bad news bit there, but there are more things than I can shake a stick at which have battered us over the last 9 months. Just a few here - Number 1 has to be that almost everybody external to OXB sees us primarily as a coronavirus vaccine company and seemed genuinely shocked that the work for AZ would tail off. None of our analysts include AZ coronavirus work in their valuations, but that was the only headline from our best ever results which went around the world and (I think) prompted our biggest ever percentage drop on results presentation day. How many more can you remember when the Chairman / acting CEO has to open by clarifying what the headline of the press release meant at the beginning of the presentation? Novartis changed their LentiVector supply contract at our request. Unfortunately the market read the Novartis release as being that they wouldn't be needing as much LentiVector and not that OXB were regaining exclusive rights and giving non-exclusive rights because they could. Sio handed our Parkinson's drug back - ostensibly because with speed of patient recruitment vs cashburn meaning they would never get there, but nobody external to OXB will see a returned drug being anything other than rejected. Even the friendly analysts know it means no more milestones / stage payments from them. OXB made a major investment and biggest ever spend right at the point the tech market chose to fold in on itself. OK, we know things are fine, that we can pay the loan and that we are moving into a very good position with regard to future co-development and manufacturing of multiple vector types. Everybody else saw the abridged version of that - big spend and loan during downturn JD's retirement will be seen in all kinds of ways, but in reality he just wants to retire. And it goes on, but all this with an impending property bubble collapse in China, a war in the Ukraine energy shock and inflation in double figures because our dear leaders thought they could defeat a chest infection by outspending it. I'm not for a minute suggesting that OXB wouldn't have dropped without this, but I am suggesting that the fall would have been nowhere near as steep. | harry s truman | |
20/6/2022 17:17 | fh, With my usual caveat here that I don't understand this, then back in 2016 when this paper was written then it seems that someone at OXB was working on herpesvirus research. Whether this is related to that tweet or not I don't know. | harry s truman | |
20/6/2022 17:10 | Hi harry....its gone up 30p on no good news....Wow. it went down more than £ 12 on no bad news...its just the chaotic world we live in....its will probably take 3 years to get back where we were 6 months ago....but keep the faith ...brilliant future mid to long term | timax333 | |
20/6/2022 15:35 | as I said last week, you want to buy Friday close or on Monday. this was obvious. Now to those shorts, most likely work for hedge funds, the recovery will be swift and you may see a bid coming. we alresdy seen Pfizer taking a stake in another vaccine company this morning. that's how large pharma / buotechs function. they acquire and acquire and acquire PLATFORMS. Buy the Sale! | qnq | |
20/6/2022 14:57 | CP, Up 7.6% on no news? So unless there's something in the background here you were obviously correct with your post last week regarding rebalancing. === chillpill 16 Jun '22 - 22:15 - 3333 of 3367 The main reason for the fall is that it is now out of the FTSE 250. It was announced at the start of the month. All rebalancing has to be done by tomorrow’s close. Generally stocks bounce after this forced selling happens. | harry s truman | |
20/6/2022 13:54 | I think just commenting, but maybe we are . Krystal Biotech involved here but unless we have collaborated with them . Not clear. OXB tweeting makes you wonder though | fhasson | |
20/6/2022 13:46 | Where we (Oxb) just commenting on that report from the tweet, or are we involved in manufacture I wonder? | philh75 | |
20/6/2022 13:42 | https://twitter.com/ | fhasson | |
20/6/2022 13:17 | Seems to be headed in an opposite direction to your guesses bodger | dominiccummings | |
20/6/2022 12:45 | CP, EBV is a herpes virus,infects about 95% of adults, but very few will develop MS. | marcusl2 | |
20/6/2022 10:18 | I’m not so sure UK property will take much of a hit.Money has to find a home.The FTSE is lower today than at the turn of the millennium.Property is the ultimate long term investment.Also,if the 1970s is anything to go by,the Lab/LiberalDemocrat coaltion lurking in the wings will inevitably screw the property market up.They’ll impose all sorts of further dictates on the rental market,landlords will withdraw properties from the market distorting supply and demand.Property prices will “cool off” for sure but i don’t see a crash. | steeplejack | |
20/6/2022 10:05 | Don’t something like 90% of the population infected with Epstein-Barr? I found out a couple of years ago I had contracted it some stage | chillpill | |
20/6/2022 08:07 | Interesting study. Scott Gottlieb, MD 🧵We always saw Epstein Barr Virus as reality of growing up, many teenagers got it. We never thought of vaxxing for it. Now we know it causes B cell cancers and probably MS. We may well vaccinate for it in future, just like we now vaccinate for HPV 1/2 | marcusl2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions